OBJECTIVE To compare the efficacy and tolerability of peripheral androgen blockade using
combined low‐dose flutamide plus finasteride vs low‐dose flutamide monotherapy for …

OBJECTIVES: To evaluate the efficacy and tolerability of combined finasteride and low-dose
flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to …

OBJECTIVES: To report the efficacy of castration after progression on finasteride and
flutamide. Standard androgen deprivation strategies for prostate cancer typically lead to …

OBJECTIVES: To evaluate the efficacy of combined finasteride and flutamide therapy in men
with advanced prostate cancer by determining (1) the short-term tolerability of finasteride …

OBJECTIVE To investigate the efficacy of low‐dose flutamide (125 mg twice daily) in the
treatment of prostate‐specific antigen (PSA) recurrence after definitive treatment with radical …

OBJECTIVES To investigate the efficacy of maximum androgen blockade (MAB) using
flutamide as second‐line hormonal therapy for advanced hormone‐refractory prostate …

Purpose: The efficacy of the combination of finasteride and flutamide in select patients with
advanced prostatic cancer is determined. Materials and Methods: A total of 22 sexually …

Objectives. Androgen ablation with luteinizing hormone-releasing hormone (LHRH)
agonists, orchiectomy, or oral estrogens has significant untoward sexual side effects. We …

Two hundred and nine patients with biopsy‐proven stage D2 prostatic carcinoma showing
disease progression after orchiectomy or treatment with DES (stilboestrol) or an LHRH …

We analyzed clinical effects of flutamide as a second‐line agent for maximum androgen
blockade (MAB) in patients with relapsing prostate cancer who received bicalutamide as the …